Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » Advancements in ADCs Using SMARTag® Technology

Advancements in ADCs Using SMARTag® Technology

Summary: Catalent’s SMARTag® technology platform offers ADC and biologics developers a one-step toolkit to develop optimized ADCs and bioconjugates. The SMARTag® technology enables site-specific, controlled drug-protein conjugation, and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.

Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.


Click here to download the Webinar